Evolution of hormonal therapy for prostate cancer
- Author(s)
- Homewood, D; Fu, MH; Sathianathen, N; La Bianca, S; Tran, B; Corcoran, NM;
- Details
- Publication Year 2024-05,Volume 53,Issue #5,Page 291-300
- Journal Title
- Australian Journal of General Practice
- Publication Type
- Review
- Abstract
- BACKGROUND: Prostate cancer (PCa) is the most common malignancy after skin cancer in men in Australia. Its management varies according to tumour stage. Due to the significant dependence on androgen receptor signalling, agents that interfere with this pathway (most commonly medical castration in the form of androgen deprivation therapy [ADT]) are the mainstay treatment of advanced disease. OBJECTIVE: This review provides a contemporary update on ADT, with further discussion of emerging novel therapies for primary care. DISCUSSION: ADT is currently indicated for the treatment of metastatic prostate cancer, disease recurrence following attempted local curative therapy, as well as combined use with radiotherapy for intermediate/high-risk disease. There has been rapid development of new pharmaceuticals targeting the androgen receptor. These are reviewed historically with an emphasis placed on emerging therapies, their common side effects, and how to manage them in the general practice setting.
- Publisher
- RACGP
- Keywords
- Humans; Male; *Prostatic Neoplasms/drug therapy; *Androgen Antagonists/therapeutic use; Antineoplastic Agents, Hormonal/therapeutic use/pharmacology; Australia
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.31128/ajgp-11-23-7028
- Open Access at Publisher's Site
https://doi.org/10.31128/ajgp-11-23-7028- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-09 08:01:44
Last Modified: 2024-07-09 08:03:53